James Nam, PharmD

Using 2 established sexual function questionnaires, researchers evaluated the effect of breast cancer treatment on sexual quality of life for survivors of the disease.

A single-center retrospective study assessed the effectiveness of serum albumin levels and BMI as prognostic measures in patients with AML.

Researchers sought to determine if NMA or reduced-intensity conditioning with busulfan improved severity/duration of oral mucositis compared with myeloablative conditioning in patients with hematologic cancer undergoing HCT.

In a phase 2 study, researchers assessed the efficacy of using a dose-escalation approach to lessen the occurrence and severity of anemia in MF treated with ruxolitinib.

In a retrospective analysis, researchers sought to determine the use of cytoreductive therapies in patients with high-risk and low-risk PV.

In an open-label study, researchers sought to determine the optimal amount of bed rest after intrathecal chemotherapy for patients with hematologic cancers.

In a systematic review, researchers explored the financial burden of treating grade 3 to 4 adverse events associated with melanoma and its treatment.

A population study of a PETALE cohort demonstrated an association between functional health domains and psychological risk in adolescent and adult survivors of cALL.

Mogamulizumab-kpkc (Poteligeo), a humanized monoclonal antibody that targets CCR4, provides a new treatment option for patients with MF and is the first FDA-approved therapy for SS.

Researchers sought to determine the impact of intensive chemotherapy on achieving complete remission and overall survival among patients with MDS or sAML.